Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL7862370 | 0.98 | CYP1A2 (0.54) | CYP1A2SIGMAR1SMN1; SMN2NAAAFKBP1A | |
| SCHEMBL6076883 | 0.98 | CYP1A2 (0.52) | CYP1A2SIGMAR1SMN1; SMN2NAAAFKBP1A | |
| SCHEMBL13313166 | 0.93 | CYP1A2 (0.54) | CYP1A2SIGMAR1NAAAFKBP1AEPHX1 | |
| SCHEMBL6079639 | 0.93 | — | — | |
| SCHEMBL27625119 | 0.91 | SIGMAR1 (0.54) | CYP1A2SIGMAR1NAAAFKBP1AEPHX1 | |
| SCHEMBL13313184 | 0.91 | SIGMAR1 (0.54) | CYP1A2SIGMAR1NAAAFKBP1AEPHX1 | |
| SCHEMBL382926 | 0.91 | CYP1A2 (0.50) | CYP1A2SIGMAR1NAAAFKBP1AEPHX1 | |
| SCHEMBL30203249 | 0.88 | SIGMAR1 (0.50) | CYP1A2SIGMAR1NAAAFKBP1AEPHX1 | |
| SCHEMBL18414169 | 0.88 | SIGMAR1 (0.50) | CYP1A2SIGMAR1NAAAFKBP1AEPHX1 | |
| Formic Acid Methyl Ester SCHEMBL28278259 | 0.88 | CYP1A2 (0.45) | CYP1A2SIGMAR1SMN1; SMN2NAAAFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030877-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030877-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230150933-A1 | BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2023-05-18 | — | — | US | disclosed |
| US-11325901-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-05-10 | — | — | US | disclosed |
| US-11220497-B2 | — | — | 2022-01-11 | — | — | US | disclosed |
| WO-2021202460-A1 | BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20200231583-A1 | Prostaglandin E Synthase Inhibitors and Methods for Utilizing the Same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-07-23 | — | — | US | disclosed |
| WO-2020069330-A2 | INHIBITORS OF VAP-1 | ACUCELA INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-2847200-B1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9150519-B2 | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis | MERCK SERONO SA (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20110171577-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING PATTERN WITH THE COMPOSITION | FUJIFILM CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| WO-2010035905-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING PATTERN WITH THE COMPOSITION | FUJIFILM CORPORATION (JP) | 2010-04-01 | — | — | WO | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | BAYER HEALTHCARE AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | BAYER HEALTHCARE AG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-4420479-A | 1-SUBSTITUTED, 2-AMINO-BENZIMIDAZOLES | ELI LILLY AND COMPANY (US) | 1983-12-13 | — | — | US | disclosed |
| EP-0091795-A1 | Olefinic benzimidazoles | ELI LILLY AND COMPANY (US) | 1983-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | LTC4S, LTB4R2, LTB4R | CYP1A2 1146/4885SIGMAR1 2420/4885SMN1; SMN2 3918/4885 |
| US-11325901-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | PTGES, PTGS1, PTGES2 | CYP1A2 46/4885SIGMAR1 1918/4885SMN1; SMN2 4027/4885 |
| US-11220497-B2 | — | PTGES, PTGS1, PTGES2 | CYP1A2 39/4885SIGMAR1 1349/4885SMN1; SMN2 3823/4885 |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | CYP1A2 4115/4885SIGMAR1 3806/4885SMN1; SMN2 3154/4885 |
| US-20200231583-A1 | Prostaglandin E Synthase Inhibitors and Methods for Utilizing the Same | PTGES, PTGS1, PTGES2 | CYP1A2 46/4885SIGMAR1 1918/4885SMN1; SMN2 4027/4885 |
| US-20110171577-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING PATTERN WITH THE COMPOSITION | ARSA, RAD51, ARID2 | CYP1A2 1453/4885SIGMAR1 2675/4885SMN1; SMN2 1102/4885 |
| US-20230150933-A1 | BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS | SARS1, ZC3HAV1, POLL | CYP1A2 1582/4885SIGMAR1 287/4885SMN1; SMN2 3872/4885 |
| US-12030877-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | PTGES, PTGS1, PTGES2 | CYP1A2 46/4885SIGMAR1 1918/4885SMN1; SMN2 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.